Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-01-21
2025-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study aims to test if the UroX™ biomarker (a measurable indicator of a biological condition) can be detected in urine samples from participants who may later test positive following a biopsy for bladder cancer. The study aims to assess the value of the biomarker as a screening tool for bladder cancer.
Patients with and those without bladder cancer are required for the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Detect the Sensitivity of the UroMark Assay
NCT02781428
The Cxbladder Rule-out of Recurrent Urothelial Carcinoma
NCT03673202
Detecting Bladder Cancer Using the UroMark Test.
NCT02676180
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
NCT06020807
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A UroX Biomarker Bladder Cancer Study patient information leaflet will be sent to all patients who are booked for these investigations, explaining the study aims and the requirements for participation.
On the day of their cystoscopy, potential participants will be approached and after signing a study specific consent form, the urine sample will be accepted, given a study number and sent for UroX biomarker testing.
These results will then be returned to the study team for comparison against the biopsy histology result to assess for sensitivity and specificity.
While cystoscopy and biopsy are the current gold standard for diagnosis of bladder cancer, it has been shown to have false-negatives of between 10-40%, due to factors such as operator error or small areas of malignancy(15-17). The possibility of a screening/outpatient test for bladder cancer with high positive predictive value would help with reduction or prioritisation of further investigations and early diagnosis of disease thus potentially allowing alternative treatment options.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with bladder cancer
50 participants with histologically confirmed evidence of malignancy for bladder cancer following routine cystoscopy and biopsy.
UroX bladder cancer biomarker test
Urine test using novel UroX biomarker test for bladder malignancy
Participants without bladder cancer
50 participants with negative biopsy for bladder cancer following routine cystoscopy and biopsy.
UroX bladder cancer biomarker test
Urine test using novel UroX biomarker test for bladder malignancy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UroX bladder cancer biomarker test
Urine test using novel UroX biomarker test for bladder malignancy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients under investigation for bladder cancer due to undergo investigative standard of care biopsy
Exclusion Criteria
* Patients who are currently undergoing radiation therapy.
* Proposed subject has no bladder (due to surgical removal).
* No cystoscopy and/or pathology information for proposed subject (following cystoscopy for final inclusion in study results)
* Patients unable or unwilling to provide consent
* Patients currently on investigational drug trials
* Patients with Catheter in Situ
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KDx Diagnostics Inc.
UNKNOWN
East and North Hertfordshire NHS Trust
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nikhil Vasdev
Role: PRINCIPAL_INVESTIGATOR
East and North Hertfordshire NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East and North Hertfordshire NHS Trust
Stevenage, Hertfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RD2018-68
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.